Latest Headlines

Latest Headlines

Juno buys into sequencing; Moderna cozies up to Big Pharma; and more from #JPM16

In the requisite flood of dealmaking that marks day one of San Francisco's annual J.P. Morgan Healthcare Conference, high-profile biotechs Juno Therapeutics and Moderna Therapeutics widened their R&D operations, while some smaller players signed deals and roped in cash to keep their projects moving.

UPDATED: Shire finally gets it done, bagging Baxalta in $32B buyout

It took a few months, but Shire has wrapped a $32 billion deal to acquire Baxalta, providing CEO Flemming Ornskov with the big merger that he has been promising investors.

The Bradner factor: Roche bags a BET inhibitor in $535M Tensha buyout

Last week, investors unveiled a $73 million startup complete with $750 million deal to pursue star Dana-Farber investigator Jay Bradner's preclinical work in developing protein degraders to fight cancer. Today, Roche is coming back to grab Tensha Therapeutics--a virtual biotech in the HealthCare Ventures stable that has an early-stage clinical program underway for Bradner's BET (bromodomain) inhibitor--in a $535 million buyout.

Wait for it--Shire could finally announce $32.5B Baxalta deal by Monday

Could Shire's months-long pursuit of Baxalta finally be coming to a close? That's the word from  Reuters, which says the Dublin drugmaker is preparing to announce its acquisition--valued at about $32.5 billion--as early as Monday. 

What's holding up the Shire-Baxalta deal? One word: Taxes

Shire and Baxalta both reportedly want to make a tie-up happen. So what's taking so long? According to the  Financial Times, the potential deal now hinges on Shire's ability to put cash in the mix without triggering a hefty tax bill. And the Dublin drugmaker won't be proceeding until it's "highly confident" in the advice it receives, the newspaper's sources say.

Charles River spends $585M on WIL Research amid a buyout spree

Charles River Laboratories extended its run of acquisitions with a $585 million buyout of WIL Research, picking up a company the CRO said will expand its global footprint and bolster its manufacturing capabilities.

PPD spins out its in-house biotech as sale rumors swirl

PPD, rumored to be up for sale, spun out its wholly owned biotech company into a stand-alone entity, a move the CRO said will maximize shareholder value.

KKR, Panasonic form newco Ascensia from Bayer Diabetes buy for $1.1B

Panasonic Healthcare has closed its purchase of the Bayer Diabetes Care business for about $1.1 billion. The deal was originally disclosed in June and was funded in part by well-known hedge fund KKR, which holds 80% of Panasonic Healthcare with the remainder owned by the larger Panasonic corporate entity.

Rapid-fire pharma M&A could stall a bit in 2016: Bloomberg

Pharma M&A is going strong so far this year, with Baxalta and Shire reportedly weighing a $32 billion-plus deal. But don't expect 2016 to best 2015 in terms of dealmaking, according to some industry watchers, who say that rapid-fire pace is likely to slow in the year ahead.

No M&A? No problem, Actelion says as it rolls out $160K-plus Uptravi

Actelion predicts it'll have a difficult time competing against its rivals for M&A targets going forward. But never fear. The company will have plenty to plow into its own development work thanks to its hefty price tag on new pulmonary arterial hypertension med Uptravi, execs said Tuesday.